Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Director Mark A. Kronenfeld acquired 1,000 shares of the company’s stock in a transaction on Friday, November 10th. The stock was acquired at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the completion of the purchase, the director now owns 6,795 shares of the company’s stock, valued at approximately $282,672. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Pacira Pharmaceuticals, Inc. (PCRX) opened at $42.75 on Tuesday. Pacira Pharmaceuticals, Inc. has a fifty-two week low of $29.81 and a fifty-two week high of $58.95. The company has a debt-to-equity ratio of 1.03, a current ratio of 6.99 and a quick ratio of 6.24.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. The firm had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The firm’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 earnings per share. research analysts expect that Pacira Pharmaceuticals, Inc. will post -0.96 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Pacira Pharmaceuticals, Inc. (PCRX) Director Mark A. Kronenfeld Acquires 1,000 Shares” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/pacira-pharmaceuticals-inc-pcrx-director-mark-a-kronenfeld-acquires-1000-shares/1702247.html.

A number of research firms have commented on PCRX. HC Wainwright restated a “buy” rating and issued a $52.00 price objective on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, November 9th. Cowen and Company restated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 2nd. Jefferies Group LLC dropped their price objective on shares of Pacira Pharmaceuticals to $52.00 and set a “buy” rating on the stock in a research note on Thursday, November 9th. Finally, Canaccord Genuity lifted their price objective on shares of Pacira Pharmaceuticals from $33.00 to $38.00 and gave the company a “hold” rating in a research note on Thursday, November 9th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. Pacira Pharmaceuticals has a consensus rating of “Hold” and an average price target of $49.71.

Hedge funds have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. purchased a new stake in Pacira Pharmaceuticals during the second quarter worth about $114,000. Benjamin F. Edwards & Company Inc. raised its position in Pacira Pharmaceuticals by 12.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock worth $133,000 after acquiring an additional 303 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Pacira Pharmaceuticals by 121.5% during the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after acquiring an additional 1,752 shares during the last quarter. QS Investors LLC acquired a new position in Pacira Pharmaceuticals during the second quarter worth about $157,000. Finally, Ameritas Investment Partners Inc. raised its position in Pacira Pharmaceuticals by 9.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after acquiring an additional 302 shares during the last quarter. 99.64% of the stock is currently owned by hedge funds and other institutional investors.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.